Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upbeat Outlook For TCM Industry

This article was originally published in PharmAsia News

Executive Summary

The Chinese government issued several policies and statutes to support the development of traditional Chinese medicine, breathing fresh life into the sector. Analysts predict that both traditional Chinese medicine sales revenues and profits are expected to grow more than 20 percent in 2008 due to several factors: Per capita health care expenditure is climbing steadily; the government is increasing investment to promote the modernization and internationalization of TCM; health reforms and medical insurance for urban and rural communities could potentially expand the medical market to 100 billion yuan; and a lower standard tax rate of 25 percent for domestic and foreign-funded companies, which will raise the profitability of the TCM industry. (Click here for more - Chinese Language)

You may also be interested in...



China Shenghuo Gains Foothold In U.S. Market With TCM Products

SHANGHAI - China Shenghuo Pharmaceutical will launch its new traditional Chinese medicine-based 12Ways Skin Care products in the U.S. during the first quarter of 2008, the company announced Feb. 7

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel